Home / Production Assistant, Diabetes In Control (page 19)

Production Assistant, Diabetes In Control

CGM Pricing

When pricing for CGM systems comes down to less than using a blood glucose monitor with strips, will you recommend these to your patients who do not take insulin?

- Yes
- No
- For my patients who are motivated
- For my patients who are not motivated

Follow the link to see how you and your colleagues compare.

Read More »

Hypertriglyceridemia Management Continued

Which of the following is accurate regarding the treatment and management of hypertriglyceridemia?

A. Pharmacologic therapy is typically initiated before lifestyle modifications in the treatment of primary and secondary dyslipidemia.
B. Patients can be treated before hypertriglyceridemia is confirmed.
C. Niacin raises LDL cholesterol levels.
D. High-potency statin monotherapy is recommended for severe or very severe hypertriglyceridemia.

Follow the link for the answer.

Read More »

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #152: Monogenic Disorders of the Beta Cell Part 2

Maturity-onset diabetes of the young (MODY) refers to group of monogenic subtypes of diabetes characterized by young onset (usually before 25 years) of non-insulin-dependent diabetes, beta-cell dysfunction that is inherited as an autosomal dominant trait. Mutations in at least 10 genes have been found to cause MODY; the common subtypes are due to mutations in GCK, Hepatocyte nuclear factor 1-alpha (HNF1A), HNF4A, and HNF1B. The definition of the underlying genes has resulted in the recognition of distinct clinical and physiologic subgroups of MODY with varying clinical course, prognosis, and treatment requirements. Classifications of diabetes by the ADA and the WHO recognize these discrete subtypes.

Read More »